TP53 and head and neck cancer: There has been development of p53 targeted adenoviral therapies to re-introduce wild type p53 which have reached phase 3 in treatment of Head and Neck cancer including other solid tumors as well as a phase 2/3 combination therapy of advanced squamous cell cancer again using genetically engineered adenovirus ONYX-15 [80].